Skip to Content

Markets in Focus :: Life Sciences Q4 2023

In the wake of the pandemic, life sciences companies were challenged to pivot to adopt new technologies and rethink existing operating models to sustain growth and deliver innovation at speeds unseen in the industry. As a result of the evolution of technology in this sector, the Food and Drug Administration (FDA) has taken significant strides in 2023 to modernize the 510(k) program and evolve guidance to incorporate technological advancements. All 510(k) submissions, unless exempted, must be submitted electronically using their eSTAR platform, which went into effect October 1, 2023. The FDA published final guidance regarding cybersecurity measures and quality system consideration concerning medical devices specific to using the 510(k) pathway.

This edition covers:

  • 2023 Year in Review
  • Regulatory Updates
  • Key Coverages to Watch
  • Guidance

Learn more in the latest Markets in Focus :: Life Sciences report.

Markets in Focus / Life Sciences Q4 2023 PDF

The views and opinions expressed within are those of the author(s) and do not necessarily reflect the official policy or position of Parker, Smith & Feek. While every effort has been taken in compiling this information to ensure that its contents are totally accurate, neither the publisher nor the author can accept liability for any inaccuracies or changed circumstances of any information herein or for the consequences of any reliance placed upon it.

Return to Articles index